Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
- Registration Number
- NCT02332954
- Lead Sponsor
- Lundbeck Canada Inc.
- Brief Summary
The purpose of the study is to describe the association/correlation between change in patient-reported cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a Major Depressive Episode (MDE).
- Detailed Description
This is an interventional, Canadian, multi-site, open-label, single cohort, flexible-dose study. The study will emulate a naturalistic real-life setting. Investigators will include Primary Care Physicians and Psychiatrists working in outpatient clinics. The study will include adult patients diagnosed with MDD according to the DSM-5™. Approximately 200 patients will be enrolled in the study. There will be approximately 100 patients who receive vortioxetine as a first treatment for the current MDE and 100 patients switched to vortioxetine due to inadequate response to their current antidepressant medication treatment. All patients will be treated with vortioxetine as per the product monograph, and at the doses determined appropriate by the investigator. The total study duration from Baseline to the end of follow-up will be approximately 56 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 226
- The patient is a man or woman, aged ≥18 years and <65 years (In the province of British Columbia, the patient must be aged 19 years or older in order to give Informed Consent)
- The patient is engaged in volunteer work or gainful employment (working ≥20 hours per week) or is enrolled full-time in post-secondary studies or vocational training.
- The patient is an outpatient consulting a Primary Care Physician or a Psychiatrist.
- Patients must have a diagnosis of MDD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5™) classification code 296.3x.
- The current MDE is confirmed by the investigator.
- The reported duration of the current MDE is at least 3 months.
- The patient has a Baseline score ≥15 on the QIDS-SR.
- The patient reports at least a minimal level of cognitive symptoms as defined by Baseline score of ≥30 on the PDQ-D-20.
- The patient is capable of communicating with the site personnel and is able to conduct the digit-symbol substitution test (DSST).
- The patient score is >69 on the DSST at Screening/Baseline.
- The patient is, in the opinion of the investigator, not able to complete all the study assessments including, but not limited to, patient-reported assessments and the DSST.
- The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features.
- The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the maximum recommended dose (according to Canadian labeling).
Other protocol defined inclusion and exclusion criteria do apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description vortioxetine naive vortioxetine vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE Switch vortioxetine vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response
- Primary Outcome Measures
Name Time Method the association/correlation between changes in patient-reported cognitive symptoms and work productivity. (Perceived Deficit Questionnaire-Depression) 12 weeks Mean change from Baseline to Week 12 in patient-reported cognitive symptoms as measured by Perceived Deficit Questionnaire-Depression-20 questions (PDQ-D-20) and work productivity as measured by Work Limitations Questionnaire (WLQ) in gainfully employed patients receiving vortioxetine for a Major Depressive Episode (MDE).
- Secondary Outcome Measures
Name Time Method Work productivity (Sheehan Disability Scale (SDS) 12 and 52 weeks mean change from baseline in work productivity as measured by Sheehan Disability Scale (SDS).
Cognitive function (PDQ-D-20) 12 and 52 weeks Mean change from baseline in cognitive symptoms as measured by PDQ-D-20.
Cognitive function (Digit Symbol Substitution Test (DSST) 12 and 52 weeks Mean change from baseline in cognitive symptoms as measured by Digit Symbol Substitution Test (DSST).
Work productivity (Work Productivity and Activity Impairment (WPAI) questionnaire) 12 and 52 weeks mean change from baseline in work productivity as measured by Work Productivity and Activity Impairment (WPAI) questionnaire.
Work productivity (WLQ) 12 and 52 weeks mean change from baseline in work productivity as measured by WLQ.
Work productivity (World Health Organization Disability Assessment Schedule-12 questions (WHODAS-12) 12 and 52 weeks mean change from baseline in work productivity as measured by World Health Organization Disability Assessment Schedule-12 questions (WHODAS-12).
Depressive symptoms (Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR) 12 and 52 weeks mean change from baseline in depressive symptoms as measured by Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR).
Depressive symptoms (Clinical Global Impression-Severity (CGI-S) 12 and 52 weeks mean change from baseline in depressive symptoms as measured by Clinical Global Impression-Severity (CGI-S).
Depressive symptoms (Clinical Global Impression-Improvement (CGI-I) score) 12 and 52 weeks mean change in depressive symptoms as measured by Clinical Global Impression-Improvement (CGI-I) score.
Trial Locations
- Locations (26)
CA029
🇨🇦Quebec, Canada
CA013
🇨🇦Chatham, Ontario, Canada
CA003
🇨🇦Mississauga, Ontario, Canada
CA023
🇨🇦Montreal, Quebec, Canada
CA026
🇨🇦Hamilton, Ontario, Canada
CA020
🇨🇦Montreal, Quebec, Canada
CA022
🇨🇦Montreal, Quebec, Canada
CA006
🇨🇦St. John's, Newfoundland and Labrador, Canada
CA007
🇨🇦Halifax, Nova Scotia, Canada
CA005
🇨🇦Kelowna, British Columbia, Canada
CA016
🇨🇦Burlington, Ontario, Canada
CA010
🇨🇦Corunna, Ontario, Canada
CA012
🇨🇦Fort Erie, Ontario, Canada
CA017
🇨🇦Hamilton, Ontario, Canada
CA015
🇨🇦St. Catharines, Ontario, Canada
CA009
🇨🇦Sarnia, Ontario, Canada
CA018
🇨🇦Pointe-Claire, Quebec, Canada
CA024
🇨🇦St-Jean-sur-Richelieu, Quebec, Canada
CA027
🇨🇦Westmount, Quebec, Canada
CA030
🇨🇦Victoriaville, Quebec, Canada
CA019
🇨🇦Quebec, Canada
CA028
🇨🇦Saskatoon, Saskatchewan, Canada
CA021
🇨🇦Quebec, Canada
CA011
🇨🇦London, Ontario, Canada
CA004
🇨🇦Edmonton, Alberta, Canada
CA008
🇨🇦Sarnia, Ontario, Canada